Evaluation of Green Tea for Improving Blood Lipid Profile

Evaluation of Heysong Japanese Green Tea for Improving Blood Lipid Function

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06992765

Enrollment

Registered

2025-05-28

Start date

2023-03-15

Completion date

2025-08-30

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Green tea, Cholesterol, Triglyceride, Blood lipid

Brief summary

The objects of this study are to evaluate the effects of the Heysong japanese green tea on the human subjects who are dyslipidemia. In this trial, 40 healthy subjects whose ages are 18\ 65 years old (20 for placebo and 20 for experimental) will be included. The total experiment will be 16 weeks and the intervention period will be 12 weeks, within which, at wk 0, 2, 8, 14 and 16, serum triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) values would be measured. Urine/feces samples and anthropometric data will also be acquired. The results will be analyzed according to the methods published by the Ministry of Health and Welfare of Taiwan Food and Drug Administration.

Interventions

DIETARY_SUPPLEMENTIntervention

2 bottles of light green tea daily containing totally 684 mg of catechin

DIETARY_SUPPLEMENTPlacebo

2 bottles of light green tea daily containing totally 108 mg of catechin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male and female. Age between 18-65 years old. * Those who have been assessed as dyslipidemia by a family physician but have not yet required medication. The following measurement values were used as evaluation criteria: 1. Hypercholesterolemia: plasma total cholesterol (TC) \>200 mg/dL; 2. Mixed hyperlipidemia: plasma total cholesterol (TC) \>200 mg/dL , triglyceride (TG) \>200 mg/dL; 3. Hypertriglyceridemia: plasma triglyceride (TG) \>200 mg/dL, and high-density lipoprotein cholesterol (HDL-C) \< 35 mg/dL or TC/HDL-C \>5.

Exclusion criteria

* Pregnant, breastfeeding, menopausal women. * Take any drugs or supplements that can affect blood lipid levels 2 weeks before or during the experiment. * People with intolerance to caffeine or green tea. * People who take drugs for chronic diseases. * People who smoke or drink alcohol.

Design outcomes

Primary

Measure	Time frame	Description
Serum total cholesterol	Wk(-2), Week(0) (Baseline), Wk(6), Wk(12) and Wk(14)	Total cholesterol is measured by the Department of Laboratory Medicine of Taipei Medical University Hospital (TMUH)

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026